The executive team were not completely forthcoming when the drug Suvodirsen failed stage 2/3 clinical trials, initially saying there would be no layoffs and that the budget for the year was secure. Two months later they changed their tune and laid off 22% of the workforce. The company is run in an extremely top-down manner, it could benefit from some stakeholder analysis and by incorporating feedback from middle management.